No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARWR240517P25000
- 1.80
- -1.20-40.00%
15min DelayClose May 14 15:59 ET
1.80High1.80Low
1.80Open3.00Pre Close1 Volume373 Open Interest25.00Strike Price180.00Turnover86.95%IV-0.48%PremiumMay 17, 2024Expiry Date2.09Intrinsic Value100Multiplier2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.8631Delta0.1255Gamma10.41Leverage Ratio-0.0616Theta-0.0014Rho-8.99Eff Leverage0.0044Vega
Intraday
- 5D
- 1D
News
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Biohaven Ltd. (BHVN) and Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Arrowhead Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Selling Arrowhead Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Even though Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has fallen by 12% over the past week , insiders who sold US$3.1m worth of stock over the past year have had less luck. Insiders would probabl
Express News | HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $90 Price Target
Express News | Arrowhead Phrmctcls Inc : Morgan Stanley Cuts Target Price to $27.00 From $36.00
Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look
Comments
Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
$Arrowhead Pharmaceuticals(ARWR.US$
$Arrowhead Pharmaceuticals(ARWR.US$
1
$Arrowhead Pharmaceuticals(ARWR.US$
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?
The company's poor performance and the CEO's high pay, despite falling earnings and shareholder value, may upset shareholders. The upcoming AGM on March 14th is a chance for shareholders to hold the board and management accountable.
$Arrowhead Pharmaceuticals(ARWR.US$ why drop today?
$Arrowhead Pharmaceuticals(ARWR.US$ such a odd spot here
Read more